Table 2 MSTCQ scores for subscales relating to injection-site reactions (ISRs), 'flu-like' symptoms (FLS), and global side-effects (GSE), by 4-week interval.
ISR score* | FLS score* | GSE score* | |||||
|---|---|---|---|---|---|---|---|
Time point | Observed | Change | Observed | Change | Observed | Change | |
Study Day 1 | n (missing) | 106 (0) | - | 106 (0) | - | 106 (0) | - |
Mean (SD) | 11.1 (3.3) | - | 9.5 (3.7) | - | 4.8 (1.7) | - | |
Median | 11.0 | - | 10.0 | - | 4.0 | - | |
(range) | (4-19) | (4-17) | (3-10) | ||||
Week 4 | n (missing) | 103 (3) | 103 (3) | 103 (3) | 103 (3) | 103 (3) | 103 (3) |
Mean (SD) | 11.4 (3.2) | 0.3 (3.3) | 8.8 (3.9) | -0.7 (3.3) | 5.5 (2.4) | 0.7 (2.3) | |
Median | 12.0 | 0.0 | 9.0 | 0.0 | 5.0 | 0.0 | |
(range) | (4-18) | (-10-9) | (4-17) | (-9-10) | (3-13) | (-4-9) | |
Week 8 | n (missing) | 100 (6) | 100 (6) | 100 (6) | 100 (6) | 100 (6) | 100 (6) |
Mean (SD) | 11.3 (3.5) | 0.2 (3.6) | 8.8 (3.8) | -0.8 (3.0) | 5.2 (2.2) | 0.5 (2.2) | |
Median | 12.0 | 0.0 | 9.0 | 0.0 | 5.0 | 0.0 | |
(range) | (4-18) | (-11-8) | (4-17) | (-11-8) | (3-12) | (-4-7) | |
Week 12/early termination | n (missing) | 106 (0) | 106 (0) | 106 (0) | 106 (0) | 106 (0) | 106 (0) |
Mean (SD) | 11.4 (3.4) | 0.3 (3.4) | 9.0 (3.8) | -0.5 (3.3) | 5.6 (2.6) | 0.8 (2.5) | |
Median | 12.0 | 0.0 | 9.0 | 0.0 | 5.0 | 0.0 | |
(range) | (4-19) | (-11-8) | (4-18) | (-7-11) | (3-14) | (-4-9) | |